A CRISPR-Cas13a system for efficient and specific therapeutic targeting of mutant KRAS for pancreatic cancer treatment
Keywords: آدنوکارسینوم پانکراس داکتال; KRAS; CRISPR-Cas13a; mRNA knockdown; Oncogenic mutation; Pancreatic cancer; Pancreatic ductal adenocarcinoma; PDAC; wild-type; WT; microbial clustered regularly interspaced short palindromic repeats; CRISPR; CRISPR-associated adaptive immune systems; CRIS